Key Insights

Highlights

Success Rate

85% trial completion

Published Results

80 trials with published results (20%)

Research Maturity

221 completed trials (56% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

9.8%

39 terminated out of 398 trials

Success Rate

85.0%

-1.5% vs benchmark

Late-Stage Pipeline

14%

54 trials in Phase 3/4

Results Transparency

36%

80 of 221 completed with results

Key Signals

80 with results85% success39 terminated

Data Visualizations

Phase Distribution

281Total
Not Applicable (103)
Early P 1 (4)
P 1 (59)
P 2 (61)
P 3 (29)
P 4 (25)

Trial Status

Completed221
Unknown56
Recruiting42
Terminated39
Active Not Recruiting19
Withdrawn10

Trial Success Rate

85.0%

Benchmark: 86.5%

Based on 221 completed trials

Clinical Trials (398)

Showing 20 of 20 trials
NCT06381596Not ApplicableCompleted

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

NCT00594672Active Not RecruitingPrimary

Age-Related Eye Disease Study (AREDS) Follow-Up

NCT01352975CompletedPrimary

Study of Dark Adaptation in Age-Related Macular Degeneration

NCT02941263CompletedPrimary

Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT02286089Phase 1Active Not RecruitingPrimary

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

NCT07496567Phase 2Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07440225Phase 2Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT06190093Phase 3Completed

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT06662162Not ApplicableRecruitingPrimary

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

NCT06164587Phase 1Completed

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

NCT06237127Not ApplicableRecruitingPrimary

Effects of Goji vs. Fiber on Macular Degeneration

NCT04516278Phase 3CompletedPrimary

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

NCT07160179Phase 1Recruiting

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT04132401Completed

AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care

NCT03848663Not ApplicableRecruitingPrimary

Visual Remapping to Aid Reading With Field Loss

NCT06970665Phase 4Active Not Recruiting

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

NCT01496625RecruitingPrimary

National Eye Institute Biorepository for Retinal Diseases

NCT03011541Not ApplicableRecruiting

Stem Cell Ophthalmology Treatment Study II

NCT06271330RecruitingPrimary

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.

NCT05300724Active Not RecruitingPrimary

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Scroll to load more

Research Network

Activity Timeline